FDA Approves Remdesivir for Hospitalized COVID-19 Patients After Drug Was Used to Treat Trump

The Food and Drug Administration (FDA) on Thursday approved remdesivir for the treatment of hospitalized COVID-19 patients.

The antiviral treatment, which is made by Gilead Sciences and sold as Veklury, was used to treat President Donald Trump after he contracted the virus earlier this month.

Remdesivir previously received emergency use authorization from the FDA in May for patients with severe cases of COVID-19. The agency later expanded its emergency use authorization in August to include patients who were hospitalized as a result of their COVID-19 infections.